Association study of vascular endothelial growth factor gene polymorphisms in endometrial carcinomas in a Japanese population

Objective: Vascular endothelial growth factor (VEGF) is one of the most potent endothelial cell mitogens and plays a critical role in angiogenesis of endometrial carcinomas. Several studies have demonstrated positive associations between VEGF gene polymorphisms and several carcinomas. In this study we investigated whether VEGF gene polymorphisms are associated with endometrial carcinomas in a Japanese population. Methods: The allele frequencies and genotype distributions of VEGF -460 C/T, +405 G/C, and +936 C/T polymorphisms were examined in 105 endometrial carcinomas and 179 controls using PCR-RFLP analysis. An association of these polymorphisms with three-year disease-free survival was evaluated using the Kaplan-Meier method. Results: No significant differences in the allele frequencies and genotype distributions of VEGF -460 C/T (p = 0.54, 0.90), +405 G/C (p = 0.31, 0.17), and +936 C/T polymorphisms (p = 0.46, 0.24) were observed between endometrial carcinoma patients and controls. There were no significant differences in the frequencies of haplotype -460 T/+405 C between patients and controls. Futhermore, VEGF 460 C/T, +405 G/C, and +936 C/T polymorphisms were not associated with three-year disease-free survival of endometrial carcinoma patients. Conclusions: Although limited by sample size, our study did not demonstrated any evidence that VEGF -460 C/T, +405 G/C, and +936 C/T polymorphisms are associated with an increased risk of endometrial carcinomas in Japanese women.

Endometrial carcinoma; Gene polymorphism; Polymerase chain reaction; Restriction fragment length polymorphism; Vascular endothelial growth factor

[1] Soliman P.T., Broaddus R.R., Schmeler K.M., Daniels M.S., Gonzalez D., Slomovitz B.M. et al.: “Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?”. J. Clin. Oncol., 2005, 23, 9344.

[2] Pistorius S., Kruger S., Hohl R., Plaschke J., Distler W., Saeger H. D. et al.: “Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients”. Gynecol. Oncol., 2006, 102, 189.

[3] Lu H., Shu X. O., Cui Y., Kataoka N., Wen W., Cai O. et al.: “Association of genetic polymorphisms in the VEGF gene with breast cancer survival”. Cancer Res., 2005, 65, 5015.

[4] Jacobsen J., Rasmuson T., Grankvist K., Liungberg B.: “Vascular endothelial growth factor as prognostic factor in renal cell carcinoma”. J. Urol., 2000, 163, 343.

[5] Sato K., Tsuchiya N., Sasaki R., Shimoda N., Satoh S., Ogawa O. et al.: “Increased serum levels of vascular endothelial growth factor in patients with renal cell cancer”. Jpn. J. Cancer Res., 1999, 90, 874.

[6] Takizawa H., Kondo K., Fujino H., Kenzaki K., Miyoshi T., Sakiyama S. et al.: “The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer”. Br. J. Cancer, 2006, 3, 75.

[7] Mazurek A., Pierzynski P., Kuc P., Kopinski P., Terlikowski S., Niklinska W. et al.: “Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer”. Neoplasma, 2004, 51, 193.

[8] Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M. et al.: “Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma”. Clin. Cancer Res., 2003, 9, 1361.

[9] Wong S. Y., Haack H., Crowlev D., Barry M., Bronson R. T., Hvnes R. O.: “Tumor secreted vascular endothelial growth factor C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis”. Cancer Res., 2005, 65, 9789.

[10] Lin C.C., Wu H.C., Tsai F.J., Chen H.Y., Chen W.C.: “Vascular endothelial growth factor gene -460 C/T polymorphism is a biomarker for prostate cancer”. Urology, 2003, 62, 374.

[11] Ku K.T., Wan L., Peng H.C., Tsai M.H., Tsai C.H., Tsai F.J.: “Vascular endothelial growth factor gene -460 C/T polymorphism is a biomarker for oral cancer”. Oral Oncol., 2005, 41, 497.

[12] Kim S.H., Choi Y.M., Choung S.H., Jun J.K., Kim J.G., Moon S.Y.: “Vascular endothelial growth factor gene +405 C/G polymorphism is associated with susceptibility to advanced stage endometriosis”. Hum. Reprod., 2005, 20, 2904.

[13] Papazoglou D., Galazios G., Koukourakis M.I,, Panagopoulos I., Kontomanolis E.N., Papatheodorou K. et al.: “Vascular endothelial growth factor gene polymorphisms and preeclampsia”. Mol. Hum. Reprod., 2004, 10, 321.

[14] Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C. et al.: “A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk”. Int. J. Cancer, 2003, 10, 468.

[15] Sfar S., Hassen E., Saad H., Mosbah F., Chouchane L.: “Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome”. Cytokine, 2006, 35, 21.

[16] Mazurek A., Pierzynski P., Kuc P., Kopinski P., Terlikowski S., Niklinska W. et al.: “Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer”. Neoplasma, 2004, 51, 193.

[17] Summers A.M., Coupes B.M., Brennan M.F., Ralph S.A., Short C.D., Brenchlev P.E.: “VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5”. Nephrol. Dial. Transplant, 2005, 20, 2427.

[18] Bhanoori M., Arvind Babu K., Pavankumar Reddy N.G., Lakshmi Rao K., Zondervan K., Deenadayal M. et al.: “The vascular endothelial growth factor (VEGF) +405 G > C 5’-untranslated region polymorphism and increased risk of endometriosis in South Indian women: a case control study”. Hum. Reprod., 2005, 20, 1844.

[19] Kariyazono H., Ohno T., Khajoee V., Ihara K., Kusuhara K., Kinukawa N. et al.: “Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease”. Pediatr. Res., 2004, 56, 953.

[20] Rueda B., Lopez-Nevot M.A., Lopez-Diaz M.J., Garcia-Porrua C., Martin J., Gonzalez-Gay M.A.: “A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis”. J. Rheumatol., 2005, 32, 1737.

[21] Boiardi L., Casali B., Nicoli D., Farnetti E., Chen O., Macchioni P. et al.: “Vascular endothelial growth factor gene polymorphisms in giant cell arteritis”. J. Rheumatol., 2003, 30, 2160.

[22] Watson C.J., Webb N.J., Bottomlev M.J., Brenchlev P.E.: “Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production”. Cytokine, 2000, 12, 1232.

[23] Abe A., Sato K., Habuchi T., Wang L., Li Z., Tsuchiya N. et al.: “Single nucleotide polymorphisms in the 3’ untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma”. Tohoku J. Exp. Med., 2002, 198, 181.